Literature DB >> 24817261

Management of advanced prostate cancer - role of the urologist.

Neal Shore1.   

Abstract

There now exists an enhanced opportunity for urologists to continue to successfully identify, treat, and manage advanced prostate cancer patients in partnership with our medical oncology and radiation oncology colleagues. For urologists and their supporting staff who are dedicated to caring for patients with advanced prostate cancer, there are novel therapies that delay disease progression, maintain - and oftentimes improve - quality-of-life metrics, and prolong overall survival. These therapies are not unusually difficult to manage, nor are they too intimidating with regard to understanding their mechanisms of action and respective safety profiles. They provide the opportunity to improve and enhance patient care, as well as to further augment the urological role in both the academic and community multidisciplinary prostate cancer clinic.

Entities:  

Mesh:

Year:  2014        PMID: 24817261     DOI: 10.1007/s11934-014-0419-0

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  12 in total

Review 1.  A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer.

Authors:  S Nilsson; P Strang; A K Aksnes; L Franzèn; P Olivier; A Pecking; J Staffurth; S Vasanthan; C Andersson; Ø S Bruland
Journal:  Eur J Cancer       Date:  2012-02-15       Impact factor: 9.162

2.  Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial.

Authors:  Christopher J Logothetis; Ethan Basch; Arturo Molina; Karim Fizazi; Scott A North; Kim N Chi; Robert J Jones; Oscar B Goodman; Paul N Mainwaring; Cora N Sternberg; Eleni Efstathiou; Dennis D Gagnon; Margaret Rothman; Yanni Hao; Cameron S Liu; Thian S Kheoh; Christopher M Haqq; Howard I Scher; Johann S de Bono
Journal:  Lancet Oncol       Date:  2012-11-09       Impact factor: 41.316

Review 3.  Urologists and oncologists: adapting to a new treatment paradigm in castration-resistant prostate cancer (CRPC).

Authors:  A Oliver Sartor; John M Fitzpatrick
Journal:  BJU Int       Date:  2012-06-19       Impact factor: 5.588

4.  Cancer statistics, 2012.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2012-01-04       Impact factor: 508.702

Review 5.  Bone related events in high risk prostate cancer.

Authors:  Sandy Srinivas; Natalia Colocci
Journal:  J Urol       Date:  2006-12       Impact factor: 7.450

Review 6.  Prevention and treatment of side-effects of systemic treatment: bone loss.

Authors:  J-J Body
Journal:  Ann Oncol       Date:  2010-10       Impact factor: 32.976

Review 7.  Bone health in men receiving androgen deprivation therapy for prostate cancer.

Authors:  James A Eastham
Journal:  J Urol       Date:  2007-01       Impact factor: 7.450

8.  Castration-resistant prostate cancer: AUA Guideline.

Authors:  Michael S Cookson; Bruce J Roth; Philipp Dahm; Christine Engstrom; Stephen J Freedland; Maha Hussain; Daniel W Lin; William T Lowrance; Mohammad Hassan Murad; William K Oh; David F Penson; Adam S Kibel
Journal:  J Urol       Date:  2013-05-09       Impact factor: 7.450

9.  Adverse effects of androgen deprivation therapy in prostate cancer: Current management issues.

Authors:  Aditya Bagrodia; Christopher J Diblasio; Robert W Wake; Ithaar H Derweesh
Journal:  Indian J Urol       Date:  2009-04

10.  Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease.

Authors:  Michael R Harrison; Terence Z Wong; Andrew J Armstrong; Daniel J George
Journal:  Cancer Manag Res       Date:  2013-01-08       Impact factor: 3.989

View more
  1 in total

1.  Multimodal imaging guided preclinical trials of vascular targeting in prostate cancer.

Authors:  James Kalmuk; Margaret Folaron; Julian Buchinger; Roberto Pili; Mukund Seshadri
Journal:  Oncotarget       Date:  2015-09-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.